Skip to main content
FDA gives breakthrough designation to AstraZeneca's Tagrisso
10/10/2017

AstraZeneca's Tagrisso, or osimertinib, which is being developed as a first-line treatment for patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer, was given breakthrough therapy status by the FDA.

Full Story: